Although in some experimental settings the variant has been shown to decrease the functionality of the CHEK2 protein [6, 16], this does not translate into significantly increased breast cancer risk in the carriers, and it is unlikely to be a significant contributor to breast cancer risk at the population level. This evidence concerns the gene CHEK2 and breast cancer.